8-K
filed April 15, 2025, 7:59 PM ET
ticker TVRD
CIK 0001346830
M&A
confidence high
sentiment neutral
materiality 0.90
Cara-Tvardi merger closes, new company renamed Tvardi Therapeutics (TVRD)
Tvardi Therapeutics, Inc.
- Merger completed April 15, 2025: Merger Sub merged into Tvardi, which became a wholly owned subsidiary.
- Post-merger ownership: pre-Cara holders ~15.4%, pre-Tvardi holders ~72.0%, Convertible Note holders ~12.5% fully diluted.
- 1-for-3 reverse stock split effected; common stock begins trading as TVRD on Nasdaq on April 16, 2025.
- Asset disposition of difelikefalin to CSL Vifor for $900K; Cara paid CSL Vifor $3M for future expenses.
- Lead candidate TTI-101 in Phase 2 for IPF; unblinded data expected H2 2025; HCC data expected H1 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Helen M. Boudreau resigned as Director at Tvardi Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Imran Alibhai, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Susan Shiff, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Wyzga was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shaheen Wirk, M.D. was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lisa von Moltke, M.D. resigned as Director at Tvardi Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sujal Shah was appointed as Director and Chair of the Board at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director and Chair of the Board
Exact text from the filing
Sujal Shah was appointed to the Company’s board of directors and as Chair of our board of directors upon the closing of the Merger.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Cynthia Smith was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Martin Vogelbaum resigned as Director at Tvardi Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey Ives, Ph.D. resigned as Director at Tvardi Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Wallace Hall was appointed as Director at Tvardi Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christopher Posner resigned as Director at Tvardi Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.